<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900809</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT-3.018</org_study_id>
    <nct_id>NCT00900809</nct_id>
  </id_info>
  <brief_title>QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia</brief_title>
  <official_title>Phase I Study of Adoptive Immunotherapy Using the Natural Killer Cell Line, Neukoplast™(NK-92), for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunityBio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NK cells from patients with malignant diseases are often functionally impaired. Their&#xD;
      function cannot be fully restored through ex vivo expansion and cytokine activation. In&#xD;
      addition, the in vivo administration of cytokines not only expands NK cells but expands&#xD;
      polyclonal T cells with no tumor specificity and no known effects.&#xD;
&#xD;
      The utilization of Neukoplast™, as a form of adoptive immunotherapy, offers several&#xD;
      advantages. Neukoplast™ represents a uniform cell population with a well-characterized&#xD;
      immunophenotype, confirmed strong anti-tumor activity and are easy to grow and expand in&#xD;
      culture, so that they can be made available in large numbers for therapeutic delivery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2014</start_date>
  <completion_date type="Actual">June 2, 2015</completion_date>
  <primary_completion_date type="Actual">June 2, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety / maximum tolerated dose of Neukoplast™ (NK-92 cell line for clinical use) in patients with refractory or relapsed acute myeloid leukemia</measure>
    <time_frame>2016</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the therapeutic efficacy of Neukoplast™ in patients with refractory or relapsed acute myeloid leukemia</measure>
    <time_frame>2016</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Neukoplast™ cell phenotype and cytotoxic activity at different time intervals after the Neukoplast™ cell infusion</measure>
    <time_frame>2016</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the presence of Neukoplast™ in the bone marrow</measure>
    <time_frame>2016</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the effects of Neukoplast™ on the host immune system, using flow cytometry and the LUMINEX multianalytic profiling system, at different time intervals after the Neukoplast™ infusion.</measure>
    <time_frame>2016</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Neukoplast™ (NK-92)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neukoplast™ will be infused in three doses.1 x 10e9 cells/m2 dose, 3 x 10e9 cells/m2 dose, 5 x 10e9 cells/m2 dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Neukoplast™ (NK-92)</intervention_name>
    <description>The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion.</description>
    <arm_group_label>Neukoplast™ (NK-92)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with refractory/relapse acute myeloid leukemia. Patients must not have&#xD;
             received radiotherapy, chemotherapy (with the exception of hydroxyurea which must be&#xD;
             discontinued 72 hours prior to therapy) or biological therapy within the preceding 2&#xD;
             weeks of the planned first Neukoplast™ cell infusion and must have recovered from any&#xD;
             adverse events due to prior administered agents&#xD;
&#xD;
          -  Assessable disease as measured by laboratory and bone marrow examinations&#xD;
&#xD;
          -  Age: Eighteen years or older&#xD;
&#xD;
          -  Performance status: ECOG ≤ 2 (Appendix A)&#xD;
&#xD;
          -  Serum creatinine &lt; 2 X upper limit of normal&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) &lt; 5 X upper limit of normal&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &lt; 5 X upper limit of normal&#xD;
&#xD;
          -  Total bilirubin &lt; 3X upper limit of normal&#xD;
&#xD;
          -  Activated partial thromboplastin time (PTT) &lt; 2.5 X upper limit of normal&#xD;
&#xD;
          -  Patients must have left ventricular ejection fraction (LVEF) ≥45 %&#xD;
&#xD;
          -  Females of child-bearing potential must have a negative pregnancy test and all&#xD;
             subjects must agree to use an effective method of contraception for up to two weeks&#xD;
             after the last infusion of Neukoplast™&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
          -  Life expectancy of greater than 3 months&#xD;
&#xD;
        Note: as many of eligible patients will be pancytopenic secondary to their disease or prior&#xD;
        therapies hematologic abnormalities will not be used as a criteria for entry or exclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with acute promyelocytic leukemia&#xD;
&#xD;
          -  Symptomatic central nervous system (CNS) involvement&#xD;
&#xD;
          -  History of congestive heart failure&#xD;
&#xD;
          -  Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated&#xD;
             respiratory, hepatic, renal, or cardiac disease).&#xD;
&#xD;
          -  Uncontrolled, life-threatening infection that is not responding to antimicrobial&#xD;
             therapy&#xD;
&#xD;
          -  ECOG performance status &gt;2 (Appendix A)&#xD;
&#xD;
          -  Hepatitis B or C or HIV positive serology&#xD;
&#xD;
          -  History of psychiatric disorder which may compromise compliance with the protocol or&#xD;
             which does not allow for appropriate informed consent&#xD;
&#xD;
          -  Patient may not be receiving any other investigational agents&#xD;
&#xD;
          -  Patient is receiving systemic anticoagulation (e.g., warfarin, intravenous heparin.&#xD;
             Low dose prophylactic anticoagulation is allowed )&#xD;
&#xD;
          -  Patient undergone autologous or allogeneic stem cell transplantation&#xD;
&#xD;
          -  Concurrent malignancy of solid tumors. Exception: Subjects who have been disease-free&#xD;
             for 5 years, or subjects with a history of completely resected non-melanoma skin&#xD;
             cancer or successfully treated in situ carcinoma are eligible. Subjects with second&#xD;
             malignancies that are indolent or definitively treated may be enrolled.&#xD;
&#xD;
          -  Pregnant or lactating female.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Boyiadzis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Cancer Center - Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Neukoplast™</keyword>
  <keyword>NK-92</keyword>
  <keyword>Refractory</keyword>
  <keyword>Refractory or Relapsed Acute Myeloid Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

